Entero Healthcare Solutions Limited — PPTs, 13-11-2024: Investor Presentation

Consolidated revenue for the quarter reached ₹1,301 crore, a robust 31% increase Year-on-Year (YoY), surpassing the Indian Pharmaceutical Market's (IPM) growth of 8%. EBITDA rose 49% YoY to ₹42 crore, with an improved margin of 3.3%, attributed to gross margin expansion and cost optimization measures. Net profit surged nearly fourfold to ₹26 crore, reflecting strong operational execution.

In the first half of FY25, Entero completed 9 strategic acquisitions, contributing ₹750 crore in revenue, enhancing its market position. The company anticipates continued revenue growth and EBITDA margin expansion driven by procurement efficiencies and a strengthened product mix, particularly in specialty pharma and medical devices.

Operationally, the company expanded its footprint, servicing over 79,500 retailers, 3,100 hospitals, and handling over 71,400 SKUs across 485 districts. Entero's position as a leading distributor in a fragmented market signals strong competitive advantages and potential for scalability, warranting attention from investors as the company is well-positioned for long-term growth opportunities.